(MedPage Today) — DENVER — Biological agents targeting interleukin-4 receptor alpha (IL-4Rα) in atopic dermatitis (AD) achieved rapid and substantial improvement in up to three-fourths of patients, according to randomized trials from China…
Source link
Ad Banner
Show Comments (0)
Hide Comments (0)
Subscribe
Login
0 Comments
Oldest
